<DOC>
	<DOCNO>NCT02168764</DOCNO>
	<brief_summary>The primary objective study demonstrate safety efficacy SPG stimulation ATI Neurostimulation System use treat acute cluster attack chronic cluster headache patient .</brief_summary>
	<brief_title>Sphenopalatine Ganglion Stimulation Treatment Chronic Cluster Headache</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Cluster Headache</mesh_term>
	<criteria>Age â‰¥22 year old . Subject diagnose chronic cluster headache accord 2013 ICHD , 3rd edition ( beta version ) , criterion 3.1.2 . Subject report minimum 4 cluster attack per week side dominant headache laterality . Subjects report 8 attack per day attack duration le 30 minute ( untreated unsuccessfully treat ) must test rule form trigeminal autonomic cephalalgia . Both subject physician judge previously currently use preventive and/or acute cluster headache treatment inadequate . Subject able distinguish cluster attack headache ( i.e. , migraine , tensiontype headache ) . Subject agree use therapy involve TENS magnetic field treatment Neurostimulator implant . Subject agree participate supplemental alternative therapy , include acupuncture spinal manipulation , Study Enrollment end Experimental Period study . Subject agree maintain current preventive headache medication regimen ( change type , frequency , dose ) except manage tolerability Study Enrollment Experimental Period study . Subject agree use acute medication , include oxygen therapy , treatable cluster attack Experimental Period use SPG stimulation therapy least 15 minute . Subject dental examination clean past six ( 6 ) month . Subject ability read comprehend , reliably record information require Protocol . Subject able provide write informed consent prior participation study . Subject 's overall health , age and/or comorbidities place subject high risk complication surgery and/or general anesthesia . Subject change type , dosage dose frequency preventive headache medication &lt; one ( 1 ) month prior study enrollment Subject diagnose form Trigeminal Autonomic Cephalalgias ( e.g. , paroxysmal hemicrania , SUNCT , etc . ) history trigeminal neuralgia . Subject undergone facial surgery area pterygopalatine fossa zygomaticomaxillary buttress ipsilateral plan implant site , opinion Investigator , may lead inability properly implant Neurostimulator . Subject currently active oral dental abscess active maxillary sinus infection base present symptom . Subject treat therapeutic radiation facial region . Subject diagnose major infectious process osteomyelitis , primary secondary malignancy involve face active require treatment past six ( 6 ) month . Subject significant pain problem ( ) , opinion Investigator , might confound study assessment . Subject woman childbearing potential pregnant , nursing , use contraception . Subject currently participate participate last month another clinical study subject , , expose investigational noninvestigational drug device . Subject demonstrate believe risk noncompliance study procedure ( e.g. , complete diary maintain stable headache medicine regimen return require followup visit ) . Subject risk unable complete least 1 year followup ( e.g. , plan relocate ) . Subject previous lesional radiofrequency ( RF ) ablation , balloon compression , gamma knife , glycerol treatment ipsilateral sphenopalatine ganglion ( SPG ) , trigeminal ganglion branch trigeminal nerve . Subject block nonlesional pulse RF ipsilateral SPG last three ( 3 ) month . Subject 's pterygomaxillary fissure le 1.2 mm width level vidian canal , determine CT scan . Subject undergone onabotulinumtoxinA injection head and/or neck occipital nerve block last three ( 3 ) month . Subject require active implanted medical device , pacemaker/defibrillator , neurostimulator , cochlear implant . Subject expect require diathermy , electroconvulsive therapy ( ECT ) , transcranial magnetic stimulation ( TMS ) . Subject history bleeding disorder coagulopathy unable discontinue anticoagulation , antiplatelet , GP IIb IIIa inhibitor medication preparation implantation procedure . In opinion Investigator , subject currently meet criterion define Diagnostic Statistical Manual Mental Disorders ( DSMIVTR ) active major depressive episode active significant psychiatric disorder , include dementia , uncontrolled general anxiety disorder , psychotic disorder uncontrolled bipolar disorder . Exclusion criterion also include : active psychosis , untreated severe anxiety disorder , homicidal ideation , significant Axis II disorder significant untreated sleep disorder . Subject currently clinically significant drug alcohol abuse define DSMIVTR unable refrain substance abuse throughout study . Subject history malignancy condition require MRI monitoring . Subject history allergic hypersensitive reaction titanium , platinum , implant grade siliconepolyurethane copolymer . Subject may , opinion Investigator , great risk infection ( e.g. , subject diabetes , take steroid , gingivitis/periodontitis , malnutrition anorexia/bulimia ) high risk harm infection . Subject currently use tobacco cessation regimen ( e.g . Wellbutrin , Zyban , Aplenzin , etc. ) . Subject suitable study reason ( include overall health , preexist condition medication ) judgment Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>